VA Disability Rating for Macular Degeneration (DC 6006): Visual Acuity, Field Loss & Service Connection (2026)

DC 6006: The AMD Rating Framework

VA rates macular degeneration and other degenerative retinal conditions under Diagnostic Code 6006 in 38 CFR Part 4, Schedule for Rating Disabilities (Organs of Special Sense). The current DC 6006 rating note states that the condition should be rated as "progressive blindness" — using the same visual acuity/visual field table system that applies to all VA eye conditions.

This means AMD is rated identically to other vision-impairing conditions: VA converts your Snellen chart acuity and visual field measurements to a combined disability percentage using the standard tables in 38 CFR § 4.84a (Table V and Table VI for acuity) and the visual field tables for field loss. The regulation requires VA to assign the higher of the two resulting ratings.

Important note: AMD primarily destroys central vision (the macula handles high-acuity central detail) while generally preserving peripheral vision until advanced stages. This means AMD typically produces dramatic acuity loss (showing up in Snellen chart measurements) while peripheral visual field testing may remain relatively intact in early-to-moderate AMD. For most AMD veterans, the acuity-based rating will be higher than the field-based rating.

Visual Acuity and Field Loss Rating Tables

VA uses a two-step process to convert visual measurements to disability percentages:

Step 1: Convert Snellen Acuity to Impairment Values (Table V)

Step 2: Combine Both Eyes Using Table VI

The combined impairment value from both eyes produces the disability rating. Examples for AMD veterans:

Service Connection for AMD: The Challenge

The primary barrier to AMD service connection is the "age-related" characterization. VA often denies AMD claims on the basis that the condition is a natural consequence of aging with no specific identifiable service nexus. This denial reasoning, while common, is legally deficient when military service factors contributed to accelerated disease progression.

The three pathways to AMD service connection:

Direct Service Connection

Direct service connection requires an identifiable in-service event — usually retinal trauma or a specific toxic exposure — that directly caused macular damage. This pathway is available but less commonly used for AMD because the disease typically has a cumulative, gradual onset rather than a single precipitating event.

Service Aggravation (Most Important for AMD)

Under 38 CFR § 3.306, a pre-existing condition that was aggravated during service — worsened beyond its natural progression — is service-connected. For AMD, aggravation service connection applies when military service factors (UV exposure, toxic chemicals, nutritional deficits, oxidative stress from combat) demonstrably accelerated AMD progression beyond what the veteran's age-related progression would have been absent those exposures.

The legal standard: the veteran must show that service exposure increased the severity of the condition beyond the natural level — the presumption of soundness (38 CFR § 3.304(b)) and benefit of the doubt (38 CFR § 3.102) both apply in the veteran's favor when evidence is approximately balanced.

Secondary Service Connection

AMD caused or accelerated by a service-connected condition or its treatment — particularly retinal toxicity from drugs prescribed for SC conditions — qualifies for secondary service connection.

Building the Aggravation Case for AMD

An aggravation nexus opinion for AMD must address two questions:

1. Did military service expose the veteran to factors known to accelerate AMD progression? (UV-B radiation, tobacco smoke, oxidative stress, toxic chemicals, nutritional deficiency)
2. Was the veteran's AMD more advanced at the time of diagnosis than would be expected for their age absent the identified military service factors?

If an ophthalmologist can answer "yes" to both with medical rationale, the aggravation opinion supports service connection. The key: VA cannot simply say "AMD is age-related" and stop there. Once a plausible aggravation nexus is presented, VA must address it with evidence or apply the benefit of the doubt in the veteran's favor.

UV Exposure in Military Service

Ultraviolet-B radiation exposure is the most extensively studied environmental accelerant of age-related macular degeneration. Cumulative UV-B damage to the retinal pigment epithelium (RPE) underlies the oxidative stress mechanism believed to accelerate AMD progression.

Military occupational categories with high UV exposure include:

• Desert operations: Soldiers serving in Southwest Asia, North Africa, and other high-altitude or desert regions face UV-B indices 3–5 times higher than temperate continental US baselines
• Maritime service: Reflection from ocean surfaces doubles effective UV exposure; coastal and blue-water sailors have among the highest occupational UV exposure in the military
• Aviation: Above 10,000 feet altitude, UV-B exposure increases 4–5% per 1,000 feet; pilots and aircrew have substantially higher UV exposure than ground personnel
• Mountain operations: High-altitude infantry and special forces operating in mountainous terrain face similar UV amplification

Veterans who served in these environments and lacked consistent UV-protective eyewear — which was not standard issue in many units until relatively recently — have a demonstrable high-UV military service history that an ophthalmologist can cite in an aggravation opinion.

Toxic Exposure and AMD

Several service-related toxic exposures have been associated with accelerated retinal pathology:

Agent Orange

Studies of Vietnam veterans with Agent Orange exposure show elevated rates of certain retinal pathologies. While AMD is not currently on VA's Agent Orange presumptive list, veterans with documented AO exposure and AMD who develop a formal ophthalmologist nexus opinion linking their specific retinal pathology to AO exposure may have a viable direct service connection claim.

Burn Pit Smoke and Combustion Products

PACT Act (2022) veterans with burn pit exposure may have a pathway to AMD service connection under the act's expansive airborne hazard provisions — particularly if they also developed other PACT Act-covered conditions suggesting systemic toxic damage. An ophthalmologist's opinion linking retinal oxidative damage to documented burn pit exposure is the key evidence.

Industrial and Chemical Exposure

Methanol, toluene, and other industrial solvents used in military maintenance operations have known retinal toxicity. Veterans in aircraft maintenance, vehicle maintenance, and other occupational specialties with documented solvent exposure should document both the exposure and any post-exposure retinal changes.

Secondary AMD Claims

The most clearly actionable secondary AMD claim involves drug-induced retinopathy:

Hydroxychloroquine (Plaquenil) Retinopathy

Hydroxychloroquine, prescribed for lupus, rheumatoid arthritis, and other autoimmune conditions, causes a characteristic "bull's-eye" maculopathy at cumulative doses. Veterans who take hydroxychloroquine for a service-connected autoimmune condition may develop retinal toxicity secondary to the SC condition's treatment. An ophthalmologist can document the characteristic retinal changes and provide a nexus opinion to the medication.

Related: VA Vision Care — Complete Guide | VA Glaucoma Rating Guide (DC 6013)

C&P Exam for Macular Degeneration

The C&P exam for AMD uses the Eyes DBQ. Preparing effectively means bringing comprehensive ophthalmology records and understanding what the examiner must evaluate:

• Snellen visual acuity in each eye with best correction — the foundation of the rating calculation
• Visual field perimetry — Humphrey 24-2 or 30-2 is standard; even if peripheral fields are normal in AMD, central field defects (central scotomas) are important to document
• OCT macula — optical coherence tomography showing drusen, retinal pigment epithelium changes, geographic atrophy, or choroidal neovascularization provides objective structural evidence
• Fundus photography — documents the extent of drusen deposits and RPE changes
• Service exposure documentation — bring records documenting UV exposure history, toxic exposure, or any other service factor supporting the aggravation claim

Wet vs. Dry AMD at the Exam

Wet AMD (neovascular AMD) typically causes more rapid, severe vision loss than dry AMD. If you have wet AMD requiring anti-VEGF injections (ranibizumab, bevacizumab, aflibercept), inform the C&P examiner. Document both your pre-treatment and post-treatment acuity, as VA should evaluate your best corrected vision at the time of the exam, but a history of severe acute vision loss from wet AMD flares is also relevant to the overall disability assessment.